Advisor Resource Council Invests $135,000 in Oncolytics Biotech Inc. (NASDAQ:ONCY)

Advisor Resource Council purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCYFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $135,000. Advisor Resource Council owned approximately 0.13% of Oncolytics Biotech at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ONCY. Ausdal Financial Partners Inc. lifted its position in shares of Oncolytics Biotech by 50.0% during the 4th quarter. Ausdal Financial Partners Inc. now owns 30,000 shares of the company’s stock worth $40,000 after buying an additional 10,000 shares in the last quarter. LPL Financial LLC purchased a new position in Oncolytics Biotech in the third quarter worth $47,000. Brave Asset Management Inc. boosted its position in Oncolytics Biotech by 150.0% in the third quarter. Brave Asset Management Inc. now owns 25,000 shares of the company’s stock worth $55,000 after purchasing an additional 15,000 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Oncolytics Biotech by 3.3% during the 3rd quarter. International Assets Investment Management LLC now owns 201,453 shares of the company’s stock valued at $449,000 after purchasing an additional 6,490 shares during the last quarter. Finally, Headinvest LLC bought a new stake in shares of Oncolytics Biotech during the 2nd quarter worth $30,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ONCY. Cantor Fitzgerald restated an “overweight” rating on shares of Oncolytics Biotech in a research report on Friday, January 12th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Oncolytics Biotech in a research report on Wednesday, February 14th.

Read Our Latest Stock Analysis on ONCY

Oncolytics Biotech Stock Performance

Shares of ONCY opened at $1.03 on Tuesday. Oncolytics Biotech Inc. has a 1 year low of $0.88 and a 1 year high of $3.39. The stock’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.44.

Oncolytics Biotech Company Profile

(Free Report)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Further Reading

Institutional Ownership by Quarter for Oncolytics Biotech (NASDAQ:ONCY)

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.